These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 2660764

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Physiological effects of reduction in lung surfactant.
    Reynolds EO.
    Proc R Soc Med; 1973 Apr; 66(4):388-9. PubMed ID: 4740402
    [No Abstract] [Full Text] [Related]

  • 44. [Experimental studies on contraindication of adrenochrome in hyaline membrane syndrome (respiratory distress syndrome)].
    Keuth U, Allardt HJ.
    Z Kinderheilkd; 1971 Apr; 111(3):205-16. PubMed ID: 5157651
    [No Abstract] [Full Text] [Related]

  • 45. [Artificial exogenous surfactants].
    Hascoët JM, Claris O.
    Arch Fr Pediatr; 1992 Apr; 49 Suppl 1():233-6. PubMed ID: 1449365
    [No Abstract] [Full Text] [Related]

  • 46. [Betamethasone in the prevention of pulmonary hyaline membrane disease: the results and applicability of G.C. Liggins' protocol].
    Scarcella A, De Filippis A, Cascioli CF, Balletta M, Rossi E, Ciccimarra F.
    Minerva Pediatr; 1983 Apr 15; 35(7):307-11. PubMed ID: 6346034
    [No Abstract] [Full Text] [Related]

  • 47. [The foam test--a prognostic sign of lung maturity of a preterm fetus].
    Petrova N, Todorova R, Gamakova N.
    Akush Ginekol (Sofiia); 1987 Apr 15; 26(1):32-5. PubMed ID: 3592107
    [No Abstract] [Full Text] [Related]

  • 48. Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants.
    Kwong MS, Egan EA, Notter RH, Shapiro DL.
    Pediatrics; 1985 Oct 15; 76(4):585-92. PubMed ID: 3900906
    [Abstract] [Full Text] [Related]

  • 49. Replacement of surfactant in hyaline membrane disease.
    Cottrell RC, Miller K.
    Br Med J (Clin Res Ed); 1984 Nov 17; 289(6455):1381-2. PubMed ID: 6437561
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Hyaline membrane disease.
    Dawson KA, DeVos D.
    Radiol Technol; 1996 Nov 17; 67(4):341-2. PubMed ID: 8778912
    [No Abstract] [Full Text] [Related]

  • 53. The effects of surfactant and antenatal corticosteroid treatment on the pulmonary pathology of preterm infants with respiratory distress syndrome.
    Teksam O, Kale G.
    Pathol Res Pract; 2009 Nov 17; 205(1):35-41. PubMed ID: 18951732
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Artificial surfactant therapy for hyaline membrane disease.
    Wigglesworth JS.
    Arch Dis Child; 1980 Oct 17; 55(10):753-4. PubMed ID: 6893647
    [No Abstract] [Full Text] [Related]

  • 56. [Pulmonary surfactant system in respiratory physiology and clinical practice].
    Motles E.
    Rev Med Chil; 1973 Jan 17; 101(1):74-83. PubMed ID: 4800565
    [No Abstract] [Full Text] [Related]

  • 57. Recent advances in diagnosis and treatment of infant lung immaturity.
    Luerti M.
    Compr Ther; 1984 Mar 17; 10(3):37-44. PubMed ID: 6546905
    [No Abstract] [Full Text] [Related]

  • 58. Replacement of surfactant in hyaline membrane disease.
    Walters DV.
    Br Med J (Clin Res Ed); 1984 Oct 06; 289(6449):855-7. PubMed ID: 6434110
    [No Abstract] [Full Text] [Related]

  • 59. Pulmonary surfactant and hyaline membrane disease.
    Nahum LH.
    Conn Med; 1966 May 06; 30(5):316-9. PubMed ID: 5936448
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.